Approval · Notice of Compliance 9872 · 2008
PRO-RABEPRAZOLE: Notice of Compliance 9872
Issued November 6, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9872
- Date
- November 6, 2008
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- H+, K+-atpase inhibitor
- Canadian reference product
- PARIET (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRO-RABEPRAZOLE | 02315181 | Cancelled Post Market |
| PRO-RABEPRAZOLE | 02315203 | Cancelled Post Market |
Medicinal ingredients
- RABEPRAZOLE SODIUM 10 MG per TAB
- RABEPRAZOLE SODIUM 20 MG per TAB